Key statistics
As of last trade Belite Bio Inc (BLTE:NAQ) traded at 51.01, -0.28% below its 52-week high of 51.15, set on Oct 04, 2024.
52-week range
Open | 51.00 |
---|---|
High | 51.15 |
Low | 50.92 |
Bid | 50.76 |
Offer | 51.00 |
Previous close | 50.99 |
Average volume | 40.64k |
---|---|
Shares outstanding | 30.61m |
Free float | 29.50m |
P/E (TTM) | -- |
Market cap | 1.56bn USD |
EPS (TTM) | -1.23 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 17:07 BST.
More ▼
Announcements
- Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease
- Belite Bio to Participate in Three Upcoming Investor Conferences
- Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
- Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
- Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
- Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results
- Belite Bio to Present at the JonesHealthcare Seaside Summit
- Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
- Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
- Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
More ▼